Company Description
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.
It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B.
It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.
The company was founded in 2015 and is headquartered in Markham, Canada.
| Country | Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Pardeep Nijhawan |
Contact Details
Address: 100 Spy Court Markham, ON L3R 5H6 Canada | |
| Phone | 289 800 9600 |
| Website | edesabiotech.com |
Stock Details
| Ticker Symbol | EDSA |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 1540159 |
| CUSIP Number | 27966L108 |
| ISIN Number | CA27966L3065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pardeep Nijhawan FRCPC, M.D. | Chief Executive Officer, Company Secretary and Director |
| Dr. Michael J. Brooks M.B.A., Ph.D. | President |
| Peter John Weiler M.B.A, M.Sc. | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2025 | 8-K | Current Report |
| Dec 12, 2025 | 424B5 | Filing |
| Dec 12, 2025 | 10-K | Annual Report |
| Dec 12, 2025 | 8-K | Current Report |
| Oct 28, 2025 | 8-K | Current Report |
| Sep 30, 2025 | 8-K | Current Report |
| Sep 9, 2025 | EFFECT | Notice of Effectiveness |
| Sep 9, 2025 | 8-K | Current Report |
| Sep 9, 2025 | 424B5 | Filing |
| Aug 8, 2025 | 10-Q | Quarterly Report |